Back to Search
Start Over
Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Apr 22; Vol. 12, pp. 649182. Date of Electronic Publication: 2021 Apr 22 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: Primary immunodeficiency is common among patients with autoimmune cytopenia.<br />Objective: The purpose of this study is to retrospectively identify key clinical features and biomarkers of primary immunodeficiency (PID) in pediatric patients with autoimmune cytopenias (AIC) so as to facilitate early diagnosis and targeted therapy.<br />Methods: Electronic medical records at a pediatric tertiary care center were reviewed. We selected 154 patients with both AIC and PID (n=17), or AIC alone (n=137) for inclusion in two cohorts. Immunoglobulin levels, vaccine titers, lymphocyte subsets (T, B and NK cells), autoantibodies, clinical characteristics, and response to treatment were recorded.<br />Results: Clinical features associated with AIC-PID included splenomegaly, short stature, and recurrent or chronic infections. PID patients were more likely to have autoimmune hemolytic anemia (AIHA) or Evans syndrome than AIC-only patients. The AIC-PID group was also distinguished by low T cells (CD3 and CD8), low immunoglobulins (IgG and IgA), and higher prevalence of autoantibodies to red blood cells, platelets or neutrophils. AIC diagnosis preceded PID diagnosis by 3 years on average, except among those with partial DiGeorge syndrome. AIC-PID patients were more likely to fail first-line treatment.<br />Conclusions: AIC patients, especially those with Evans syndrome or AIHA, should be evaluated for PID. Lymphocyte subsets and immune globulins serve as a rapid screen for underlying PID. Early detection of patients with comorbid PID and AIC may improve treatment outcomes. Prospective studies are needed to confirm the diagnostic clues identified and to guide targeted therapy.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Westermann-Clark, Meehan, Meyer, Dasso, Amre, Ellison, Patel, Betensky, Hauk, Mayer, Metts, Leiding, Sriaroon, Kumar, Ayala and Walter.)
- Subjects :
- Adolescent
Anemia, Hemolytic, Autoimmune drug therapy
Anemia, Hemolytic, Autoimmune genetics
Child
Child, Preschool
Female
Humans
Infant
Lymphocyte Subsets drug effects
Lymphocyte Subsets metabolism
Male
Mutation
Primary Immunodeficiency Diseases drug therapy
Primary Immunodeficiency Diseases genetics
Purpura, Thrombocytopenic, Idiopathic drug therapy
Purpura, Thrombocytopenic, Idiopathic genetics
Retrospective Studies
Thrombocytopenia drug therapy
Thrombocytopenia genetics
Treatment Outcome
Anemia, Hemolytic, Autoimmune immunology
Autoantibodies immunology
Lymphocyte Subsets immunology
Primary Immunodeficiency Diseases immunology
Purpura, Thrombocytopenic, Idiopathic immunology
Thrombocytopenia immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33968040
- Full Text :
- https://doi.org/10.3389/fimmu.2021.649182